Loading...

BGMS BIO GREEN MED SOLUTION INC Capital Structure Changes 8-K Filing

B GR

BGMS

BIO GREEN MED SOLUTION INC

(BGMS)

2025 8-K

Summary

Summary

Logo Correction

Compliance Notice

Company Acquisition

Shareholder Meeting Results

Warrant Exchange Agreement

Stock Warrants Amended

Audit Firm Changes

Q2 2025 Results

Financial Statements Filed

Removal of Ownership Limita...

Asset Acquisitions

Reverse Stock Split

Equity Offerings

Increase in Dividend Rate

Financial Statements

Merger of Equals

Dividend Declaration

Management Changes

Securities Agreement

Leadership Changes

Share Purchase Agreement

Stock Amendments

Capital Structure Changes

Subsidiary Liquidation

Agreement Amendment

Stock Sale Agreement

Q3 Financial Results

Nasdaq Delisting Risk

Dividend Suspension

Nasdaq Delisting Risk

Nasdaq Compliance Issue

Accounting Firm Change

Financial Results

Annual Meeting and Manageme...

Earnings Reports

Private Placement

Earnings Reports

Management Changes

Dividend Declaration

Investor Conferences

Compliance with Nasdaq mini...

Securities Purchase Agreement

Special Meeting

Restatement of Financial St...

Earnings Reports

Bylaw Amendment

Dividend Declaration

Earnings Reports

Annual Meeting and Dividend...

Earnings Reports

Renewal of Employment Agree...

Regulation FD Disclosure

Dividend Declaration

Earnings Reports

External Links:

Cyclacel Pharmaceuticals amended its Series C and Series D Convertible Preferred Stock rights to remove ownership limitations and increased authorized common stock from 100 million to 250 million shares.

AI Assistant

BIO GREEN MED SOLUTION INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.